A study evaluated four immunosuppressive regimens for renal transplant recipients, comparing standard-dose cyclosporine, low-dose tacrolimus, low-dose cyclosporine, and low-dose sirolimus, all combined with daclizumab induction and mycophenolate mofetil and corticosteroids. The primary endpoint was estimated glomerular filtration rate (eGFR) 12 months post-transplantation, with secondary endpoints including acute rejection and allograft survival. The study found that the low-dose tacrolimus group had the highest eGFR (65.4 ml/min) compared to the other groups (56.7-59.4 ml/min). The rate of biopsy-proven acute rejection was lower in the low-dose tacrolimus group (12.3%) than in the other groups. Allograft survival was highest in the low-dose tacrolimus group (94.2%), followed by the low-dose cyclosporine group (93.1%). Serious adverse events were more common in the low-dose sirolimus group (53.2%) than in the other groups. The low-dose tacrolimus regimen provided better renal function, allograft survival, and lower acute rejection rates compared to other regimens. The study concluded that the low-dose tacrolimus regimen may be advantageous for renal function, allograft survival, and acute rejection rates. The study was supported by Hoffmann–La Roche.A study evaluated four immunosuppressive regimens for renal transplant recipients, comparing standard-dose cyclosporine, low-dose tacrolimus, low-dose cyclosporine, and low-dose sirolimus, all combined with daclizumab induction and mycophenolate mofetil and corticosteroids. The primary endpoint was estimated glomerular filtration rate (eGFR) 12 months post-transplantation, with secondary endpoints including acute rejection and allograft survival. The study found that the low-dose tacrolimus group had the highest eGFR (65.4 ml/min) compared to the other groups (56.7-59.4 ml/min). The rate of biopsy-proven acute rejection was lower in the low-dose tacrolimus group (12.3%) than in the other groups. Allograft survival was highest in the low-dose tacrolimus group (94.2%), followed by the low-dose cyclosporine group (93.1%). Serious adverse events were more common in the low-dose sirolimus group (53.2%) than in the other groups. The low-dose tacrolimus regimen provided better renal function, allograft survival, and lower acute rejection rates compared to other regimens. The study concluded that the low-dose tacrolimus regimen may be advantageous for renal function, allograft survival, and acute rejection rates. The study was supported by Hoffmann–La Roche.